CEL-SCI Corporation (CVM)
| Market Cap | 84.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.05M |
| Shares Out | 53.98M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,075 |
| Open | 1.540 |
| Previous Close | 1.500 |
| Day's Range | 1.500 - 1.570 |
| 52-Week Range | 1.040 - 3.230 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+541.03%) |
| Earnings Date | May 10, 2024 |
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune sy... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CVM stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content
NEW YORK--(BUSINESS WIRE)--Channel V Media (CVM), a communications strategy and PR firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today annou...
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI's LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.
CEL-SCI Corporation Issues Letter to Shareholders
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation issues letter to shareholders.
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results.
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $7.75 million public offering of common stock.
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces pricing of $7.75 million public offering of common stock.
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI completes commissioning of its Multikine manufacturing facility for commercial scale production of head & neck cancer drug.
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--European Medicines Agency grants CEL-SCI a waiver of strict pediatric requirements, clearing the path towards marketing authorization for Multikine.
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2023 financial results and clinical & corporate developments.
UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--UK'S National Institute for Health and Care Excellence (NICE) selects Multikine as potential new standard of care for head & neck cancer.
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $5 million public offering of common stock.
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $5 million offering of common stock.
CEL-SCI Issues Letter to Shareholders
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI issues letter to shareholders.
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals.
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2023--5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, as Presented at Leading Cancer Conference ESMO 2023.
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI readies its Multikine manufacturing facility for commercial scale production.
CEL-SCI Files Request With the UK's MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI files request with the UK'S MHRA regarding path to approval for Multikine in the treatment of head & neck cancer.
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI submits scientific advice filing To European Medicines Agency (EMA) for Multikine in the treatment of Head & Neck Cancer.
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2023 financial results.
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of public offering.
CEL-SCI Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of public offering.
CEL-SCI Announces Proposed Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces proposed public offering of common stock.
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine's Approval for Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI concludes positive meeting with U.S. FDA concerning Multikine's approval for head & neck cancer.
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #AHNS2023--CEL-SCI reports Phase 3 Tumor PD-L1 Biomarker Data demonstrate Multikine's increased efficacy and potential for combination with checkpoint inhibitors.
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to present novel data at AHNS 11th International Conference on Head and Neck Cancer—new patent to be filed.